Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.
The 2023 SABCS® was a huge success, with record attendance and number of submitted abstracts. The premier symposium for breast cancer research, care, and advocacy had plenty of new features, as well as the robust science that is the meeting’s hallmark.
Heide L. Ford, PhD; Jennifer K. Richer, PhD; Ann Partridge, MD, MPH; and Mariana Chavez Mac Gregor, MD, MSC, FASCO, outlined updates across the spectrum of breast cancer research and clinical practice.
Experts reviewed the updates from the 2023 SABCS® that may have an immediate impact for patients and physicians.
Vivek Subbiah, MD, and fellow panelists explored how genomics are driving a new era of tumor-agnostic therapies for cancer in which drugs are approved for biomarkers rather than cancer types.
Findings from 11 studies were presented Friday during the third and final General Session of the 2023 SABCS®.
Alana L. Welm, PhD, on Friday discussed what she was doing to model metastatic breast tumors using patient-derived xenografts and organoids, and she implored her fellow researchers to work together to advance the field.
Audience members brought real-world clinical cases and concerns before a multidisciplinary panel on Thursday, prompting discussions about choosing optimal care and treatment for patients with breast cancer in routine practice.
Pedram Razavi, MD, PhD, moderated a Wednesday session that leveraged challenging, complex clinical cases to highlight how the range of expertise of a molecular tumor board (MTB) can inform and help optimize patient care and treatment in real-world practice.
AACR Distinguished Lectureship recipient Kornelia Polyak, MD, PhD, FAACR, on Thursday discussed her work on disease transition and profiling the different cell types involved in different stages of breast disease.
Presenters including Calvin J. Kuo, MD, PhD, discussed basic science developments such as the role of organoids, single-cell sequencing, clinical genomics, and molecular docking.